The patent landscape for dexlansoprazole is complex and involves multiple patent families covering different aspects of the drug, including its formulation and methods of use [1].
When do dexlansoprazole patents expire?
The expiration dates for dexlansoprazole patents vary. For example, U.S. Patent No. 6,998,309, related to extended-release formulations, expired in 2023 [2]. However, other patents may still be in effect or have recently expired, influencing market exclusivity [1]. Information on specific patent expiration dates can be found on resources like DrugPatentWatch.com [1].
Why are companies challenging dexlansoprazole patents?
Challenges to dexlansoprazole patents are often initiated by generic drug manufacturers seeking to enter the market before the expiration of existing patents [3]. These challenges can involve arguing that the patents are invalid or that their products do not infringe on the patent claims. Litigation surrounding these patents can be a significant factor in determining market entry for generic versions [3].
How does dexlansoprazole work?
Dexlansoprazole is a proton pump inhibitor (PPI) used to treat gastroesophageal reflux disease (GERD) and related conditions [4]. It works by reducing the amount of acid produced in the stomach [4]. The extended-release formulation of dexlansoprazole is designed to release the active ingredient in two distinct phases, providing longer-lasting acid suppression compared to some other PPIs [5].
What are the alternatives to dexlansoprazole?
Other proton pump inhibitors, such as omeprazole, lansoprazole, pantoprazole, and esomeprazole, are available as alternatives to dexlansoprazole. H2 receptor antagonists are another class of medications used to reduce stomach acid, though they are generally considered less potent than PPIs [6].
Who manufactures dexlansoprazole?
Takeda Pharmaceuticals originally developed and marketed dexlansoprazole under the brand name Dexilant [7]. Following patent expirations, generic versions of dexlansoprazole are now manufactured by various pharmaceutical companies [3].
What are the risks associated with dexlansoprazole?
Like other PPIs, dexlansoprazole carries potential risks and side effects. Long-term use of PPIs has been associated with an increased risk of bone fractures, vitamin B12 deficiency, and certain kidney problems [8]. Patients should discuss these risks with their healthcare providers [8].
Sources:
[1] https://www.drugpatentwatch.com/dexlansoprazole/patents
[2] https://www.google.com/patents/US6998309B2
[3] https://www.fiercepharma.com/pharma/takedas-dexilant-patent-fight-heats-generic-makers-line-up
[4] https://www.rxlist.com/dexilant-drug.htm
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3091422/
[6] https://www.mayoclinic.org/diseases-conditions/gerd/diagnosis-treatment/drc-20361945
[7] https://www.takeda.com/newsroom/news-releases/2009/takeda-announces-fda-approval-of-dexilant-lansoprazole-delayed-release-capsules/
[8] https://www.fda.gov/drugs/drug-safety-and-availability/drug-safety-communication-fda-reminds-public-about-potential-risks-associated-long-term-use-proton